We have to apologize for the video quality. Ali’s recording corrupted.
Ali Pashazadeh — Founder & CEO, Treehill Partners | Practicing Surgeon | Former Goldman Sachs, UBS, Blackstone
Founder and CEO of Treehill Partners, a global healthcare strategic and transaction advisory firm. Career spans 30+ years as researcher, practicing trauma surgeon, and healthcare investment banker. Continues to practice emergency medicine alongside advisory work, giving him a unique perspective on both the investment side and the patient side of healthcare.
Jon Rees — CEO & Co-founder, MitoRx Therapeutics
CEO and Co-founder of MitoRx Therapeutics, developing small molecule treatments targeting mitochondria to treat metabolic disease without appetite suppression.
In This Episode We Discuss
- Why GLP-1s hit $13 billion in Q1 2026 — the highest-selling drug class in the world
- Benefits beyond weight loss: neurological, renal, and cardiovascular improvements
- Atypical side effects Ali is seeing in the ER: kidney stones, visual disturbances
- Why appetite suppression is fundamentally a starvation response — and the cost is muscle loss
- MitoRx’s approach: targeting mitochondria instead of appetite, no food restriction required
- How clinical development costs have increased 4x in less than 10 years
- Why Ali left full-time medicine after watching a team argue for 6 hours over a breast cancer patient’s surgery
- What Jon wants on his gravestone — and how that question changed his career
Show Notes / Resources
Companies:
- Treehill Partners
International strategic and financial advisory focused exclusively on healthcare - MitoRx Therapeutics
Developing novel therapeutics that reverse mitochondrial dysfunction
Guest LinkedIn:
Company LinkedIn:
